Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track?
· insidermonkey.com
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) closed 58% higher at $6.65 on August 14 after the company said the FDA was willing to review an amendment containing 2...